10.50
-0.42(-3.85%)
Currency In USD
| Previous Close | 10.92 |
| Open | 11.02 |
| Day High | 11.02 |
| Day Low | 10.04 |
| 52-Week High | 12.34 |
| 52-Week Low | 2.24 |
| Volume | 1.19M |
| Average Volume | 797,809 |
| Market Cap | 490.34M |
| PE | -2.97 |
| EPS | -3.53 |
| Moving Average 50 Days | 8.91 |
| Moving Average 200 Days | 5.48 |
| Change | -0.42 |
If you invested $1000 in 4D Molecular Therapeutics, Inc. (FDMT) since IPO date, it would be worth $259.26 as of November 08, 2025 at a share price of $10.5. Whereas If you bought $1000 worth of 4D Molecular Therapeutics, Inc. (FDMT) shares 3 years ago, it would be worth $1,294.7 as of November 08, 2025 at a share price of $10.5.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
4DMT to Participate in Jefferies 2025 London Healthcare Conference
GlobeNewswire Inc.
Nov 06, 2025 9:05 PM GMT
EMERYVILLE, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatmen
4DMT Announces Pricing of $100 Million Offering of Common Stock and Pre-Funded Warrants
GlobeNewswire Inc.
Nov 06, 2025 11:23 AM GMT
EMERYVILLE, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatmen
4DMT Announces Positive Long-Term Data from Phase 1/2 PRISM Clinical Trial in Wet AMD Supporting 4D-150’s Potential as a Backbone Therapy with Consistent and Durable Benefit over Multiple Years
GlobeNewswire Inc.
Nov 06, 2025 11:00 AM GMT
4D-150 demonstrated consistent and durable benefit across all three patient cohorts as evidenced by maintenance of visual acuity, control of retinal anatomy and reduction of treatment burden at all time points with up to 2 years of follow-upStrong do